🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04255524
Starting soon Not applicable

Choroidal Change on OCTA in Eyes With High Myopia

NCT04255524 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Not applicable
Started
2020-02-01
Last updated
2020-02-05

Condition(s) studied

Myopia, ProgressiveChoroid Disease

Investigational drug(s) / intervention(s)

Optic coherence tomography angiography (OCTA)

Optic coherence tomography angiography (OCTA): Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map

Study summary

Myopia is a global healthy concern, especially the high myopia and pathological myopia among Asian populations. However, its mechanism still remains largely unclear. Recent findings suggested choroidal changes might be related to the development of myopia. This study is to useOCT angiography (OCT-A) to investigate parapapillary choroidal microvasculature change in myopic eyes, and try to find the cause-and-effect relationship between choroidal change and the development of myopia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Spherical equivalent measurement can be included in above 4 groups 2. Willing to be followed up in the future 10 years Exclusion Criteria: 1. Deny to sign the patient consent, or deny to be followed 2. Evidence of cardiac, or diabetic, or CNS disease. 3. Clinically diagnosed with retinal or choroidal disease 4. Glucoma 5. Cataract or corneal disease that influence the quality of fundus OCTA image

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu

More The First Affiliated Hospital with Nanjing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04255524 on ClinicalTrials.gov ↗ ← All trials in China